Allianz Asset Management GmbH - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 199 filers reported holding DENALI THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.

Quarter-by-quarter ownership
Allianz Asset Management GmbH ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$303,261
-30.1%
14,7000.0%0.00%0.0%
Q2 2023$433,797
+66.6%
14,700
+30.1%
0.00%
Q1 2023$260,352
-17.2%
11,3000.0%0.00%
-100.0%
Q4 2022$314,253
-9.4%
11,3000.0%0.00%0.0%
Q3 2022$347,000
-20.4%
11,300
-23.8%
0.00%
Q2 2022$436,000
-24.0%
14,820
-16.8%
0.00%
Q1 2022$574,000
-64.5%
17,820
-50.7%
0.00%
-100.0%
Q4 2021$1,615,000
+70.9%
36,145
+92.9%
0.00%0.0%
Q3 2021$945,000
-48.6%
18,735
-20.1%
0.00%
-50.0%
Q2 2021$1,840,000
+37.3%
23,4550.0%0.00%
+100.0%
Q1 2021$1,340,000
-50.4%
23,455
-27.3%
0.00%
-66.7%
Q4 2020$2,702,000
+368.3%
32,260
-2.7%
0.00%
+200.0%
Q4 2019$577,000
-39.4%
33,154
-45.8%
0.00%0.0%
Q3 2019$952,000
-25.2%
61,216
-0.1%
0.00%0.0%
Q2 2019$1,272,000
-45.1%
61,261
-38.6%
0.00%
-50.0%
Q1 2019$2,318,000
+24.4%
99,822
+9.4%
0.00%0.0%
Q4 2018$1,864,000
-61.6%
91,204
-59.2%
0.00%
-50.0%
Q3 2018$4,854,000
+34.4%
223,280
-5.7%
0.00%0.0%
Q2 2018$3,611,000
-22.4%
236,790
+0.2%
0.00%0.0%
Q1 2018$4,653,000
+49.1%
236,290
+18.4%
0.00%
+100.0%
Q4 2017$3,121,000199,5450.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q3 2022
NameSharesValueWeighting ↓
Crestline Management, LP 7,460,732$240,012,00028.78%
Casdin Capital, LLC 1,500,000$48,255,0002.16%
Flagship Pioneering Inc. 2,619,968$84,284,0001.98%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 38,000$8,192,0001.85%
Yiheng Capital Management, L.P. 1,014,684$32,642,0001.49%
SECTORAL ASSET MANAGEMENT INC 207,100$6,662,0001.18%
Artal Group S.A. 600,000$19,302,0000.81%
GILDER GAGNON HOWE & CO LLC 2,619,217$84,260,0000.78%
Temasek Holdings (Private) Ltd 5,369,487$172,736,3970.73%
BRANDYWINE MANAGERS, LLC 9,601$309,0000.53%
View complete list of DENALI THERAPEUTICS INC shareholders